Crystal problem highlighted in US complete response to Neupro
This article was originally published in Scrip
Executive Summary
UCBneeds to resolve the issue of crystal formation in its patch formulation of rotigotine (Neupro) before it can be approved in the US for advanced Parkinson's disease and primary restless legs syndrome (RLS), the FDAhas told the company in a complete response letter.